NEWS

WIRES

OTHER

Cord Blood America Announces Contract With BioE; Provides Clients Highest Quality, 'State of the Art' Processing System for Cord Blood Storage

The PrepaCyte CB Processing System:

    --  Provides optimum stem cell recoveries on each cord blood unit processed.
    --  Ensures the sterility and integrity of the cord blood unit.
    --  Removes 99.5 percent of the unnecessary red cells, which offers a more
        pure concentration of stem cells compared to any other product or method
        in the industry.

"BioE's cord blood processing system helps Cord Blood America meet its objective of providing the highest quality of cord blood storage for our clients," said Matthew Schissler, co-founder and CEO. "We are committed to offering our clients an unsurpassed level of processing and storage quality. The BioE system does just that; one that our shareholders can revel in, and comforts our customers."

About BioE, Inc.

Headquartered in St. Paul, Minn., BioE is a biomedical company that provides enabling cord blood stem cell tools and technologies. The Company's proprietary PrepaCyte® CB Processing System easily and efficiently separates stem cells from cord blood for cryopreservation and eventual transplantation in humans. BioE's clonal, cord blood-derived Multi-Lineage Progenitor Cell(TM) (MLPC(TM)) stem cell - isolated using the company's PrepaCyte cell separation platform - can differentiate into multiple cell types and lineages and is readily available to clinicians and researchers for therapeutic research and drug discovery. For more information about the company, visit www.bioe.com or contact Gayl Chrysler at (800)350-6466 (gchrysler@bioe.com).

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

    CONTACT:
    Paul Knopick
    E & E Communications
    949/707-5365
    pknopick@eandecommunications.com

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

SOURCE Cord Blood America, Inc.